Modern Management of Familial Hypercholesterolemia

P. Barton Duell, Ishwarlal Jialal

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Familial hypercholesterolemia (FH) is a common genetic disorder that can manifest clinically as both the severe homozygous (HoFH) form that often presents in childhood and the commoner heterozygous (HeFH) form that is typically identified in adults. The majority of genetic causes are due to defects in low-density lipoprotein (LDL) receptor synthesis and action. Until recently, it was exceedingly difficult to achieve the goal of a 50% reduction in LDL-cholesterol or LDL-C < 70-100 in these patients. Established therapies include statins, niacin, bile-acid sequestrants, and ezetimibe in various combinations. The recent advent of monoclonal antibodies to PCSK9 (evolocumab and alirocumab) has revolutionized the management of FH and results in a substantial reduction in LDL-C and also reductions in Lp(a). In addition, the previous ushering in of antisense therapy against apoB (mipomersen) and inhibition of microsomal transfer protein (lomitapide) for use in HoFH greatly enhanced our ability to manage refractory hypercholesterolemia in these patients. Hence, the therapeutic landscape for this common disorder has changed dramatically for these patients, with a strong promise for a reduction in cardiovascular events.

Original languageEnglish (US)
Pages (from-to)463-467
Number of pages5
JournalMetabolic Syndrome and Related Disorders
Volume14
Issue number10
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Hyperlipoproteinemia Type II
LDL Lipoproteins
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inborn Genetic Diseases
LDL Receptors
Niacin
Apolipoproteins B
Hypercholesterolemia
Bile Acids and Salts
LDL Cholesterol
Therapeutics
Monoclonal Antibodies
Proteins

Keywords

  • atherosclerosis
  • familial hypercholesterolemia
  • FH
  • LDL cholesterol/LDL
  • PCSK9
  • prevention

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Modern Management of Familial Hypercholesterolemia. / Duell, P. Barton; Jialal, Ishwarlal.

In: Metabolic Syndrome and Related Disorders, Vol. 14, No. 10, 01.12.2016, p. 463-467.

Research output: Contribution to journalReview article

Duell, P. Barton ; Jialal, Ishwarlal. / Modern Management of Familial Hypercholesterolemia. In: Metabolic Syndrome and Related Disorders. 2016 ; Vol. 14, No. 10. pp. 463-467.
@article{19d41647c61f45e0a40bdc8edd291189,
title = "Modern Management of Familial Hypercholesterolemia",
abstract = "Familial hypercholesterolemia (FH) is a common genetic disorder that can manifest clinically as both the severe homozygous (HoFH) form that often presents in childhood and the commoner heterozygous (HeFH) form that is typically identified in adults. The majority of genetic causes are due to defects in low-density lipoprotein (LDL) receptor synthesis and action. Until recently, it was exceedingly difficult to achieve the goal of a 50{\%} reduction in LDL-cholesterol or LDL-C < 70-100 in these patients. Established therapies include statins, niacin, bile-acid sequestrants, and ezetimibe in various combinations. The recent advent of monoclonal antibodies to PCSK9 (evolocumab and alirocumab) has revolutionized the management of FH and results in a substantial reduction in LDL-C and also reductions in Lp(a). In addition, the previous ushering in of antisense therapy against apoB (mipomersen) and inhibition of microsomal transfer protein (lomitapide) for use in HoFH greatly enhanced our ability to manage refractory hypercholesterolemia in these patients. Hence, the therapeutic landscape for this common disorder has changed dramatically for these patients, with a strong promise for a reduction in cardiovascular events.",
keywords = "atherosclerosis, familial hypercholesterolemia, FH, LDL cholesterol/LDL, PCSK9, prevention",
author = "Duell, {P. Barton} and Ishwarlal Jialal",
year = "2016",
month = "12",
day = "1",
doi = "10.1089/met.2016.29011.due",
language = "English (US)",
volume = "14",
pages = "463--467",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Modern Management of Familial Hypercholesterolemia

AU - Duell, P. Barton

AU - Jialal, Ishwarlal

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Familial hypercholesterolemia (FH) is a common genetic disorder that can manifest clinically as both the severe homozygous (HoFH) form that often presents in childhood and the commoner heterozygous (HeFH) form that is typically identified in adults. The majority of genetic causes are due to defects in low-density lipoprotein (LDL) receptor synthesis and action. Until recently, it was exceedingly difficult to achieve the goal of a 50% reduction in LDL-cholesterol or LDL-C < 70-100 in these patients. Established therapies include statins, niacin, bile-acid sequestrants, and ezetimibe in various combinations. The recent advent of monoclonal antibodies to PCSK9 (evolocumab and alirocumab) has revolutionized the management of FH and results in a substantial reduction in LDL-C and also reductions in Lp(a). In addition, the previous ushering in of antisense therapy against apoB (mipomersen) and inhibition of microsomal transfer protein (lomitapide) for use in HoFH greatly enhanced our ability to manage refractory hypercholesterolemia in these patients. Hence, the therapeutic landscape for this common disorder has changed dramatically for these patients, with a strong promise for a reduction in cardiovascular events.

AB - Familial hypercholesterolemia (FH) is a common genetic disorder that can manifest clinically as both the severe homozygous (HoFH) form that often presents in childhood and the commoner heterozygous (HeFH) form that is typically identified in adults. The majority of genetic causes are due to defects in low-density lipoprotein (LDL) receptor synthesis and action. Until recently, it was exceedingly difficult to achieve the goal of a 50% reduction in LDL-cholesterol or LDL-C < 70-100 in these patients. Established therapies include statins, niacin, bile-acid sequestrants, and ezetimibe in various combinations. The recent advent of monoclonal antibodies to PCSK9 (evolocumab and alirocumab) has revolutionized the management of FH and results in a substantial reduction in LDL-C and also reductions in Lp(a). In addition, the previous ushering in of antisense therapy against apoB (mipomersen) and inhibition of microsomal transfer protein (lomitapide) for use in HoFH greatly enhanced our ability to manage refractory hypercholesterolemia in these patients. Hence, the therapeutic landscape for this common disorder has changed dramatically for these patients, with a strong promise for a reduction in cardiovascular events.

KW - atherosclerosis

KW - familial hypercholesterolemia

KW - FH

KW - LDL cholesterol/LDL

KW - PCSK9

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=85020513771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020513771&partnerID=8YFLogxK

U2 - 10.1089/met.2016.29011.due

DO - 10.1089/met.2016.29011.due

M3 - Review article

VL - 14

SP - 463

EP - 467

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 10

ER -